Sabby Healthcare Master Fund, Ltd.
CIK 0001561018 Name as filed on the most recent filing
Filed as Sabby Healthcare Master Fund, Ltd. (4)· Sabby Healthcare Volatility Master Fund, Ltd. (6)
51 transaction lines · from 10 filings · filed 2014-03-24 to 2018-04-27 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2018-04-26 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 7,085 acquired | 0.35 | 2,479.75 | Form 4, filing 0001535610-18-000082 | |
| 2018-03-16 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 33,413 acquired | 0.44 | 14,544.68 | Form 4, filing 0001535610-18-000070 | |
| 2018-03-16 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 20,229 acquired | 0.43 | 8,619.58 | Form 4, filing 0001535610-18-000070 | |
| 2018-03-16 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 9,247 acquired | 0.43 | 3,970.66 | Form 4, filing 0001535610-18-000070 | |
| 2018-03-16 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 1,400 acquired | 0.42 | 589.54 | Form 4, filing 0001535610-18-000070 | |
| 2018-03-16 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 9 acquired | 0.42 | 3.78 | Form 4, filing 0001535610-18-000070 | |
| 2018-03-15 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 15,025 acquired | 0.42 | 6,318.01 | Form 4, filing 0001535610-18-000069 | |
| 2018-03-15 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 14,400 acquired | 0.42 | 6,055.20 | Form 4, filing 0001535610-18-000069 | |
| 2018-03-15 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 13,545 acquired | 0.42 | 5,688.90 | Form 4, filing 0001535610-18-000069 | |
| 2018-03-15 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 3,566 acquired | 0.42 | 1,497.72 | Form 4, filing 0001535610-18-000069 | |
| 2018-03-15 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 34 acquired | 0.42 | 14.28 | Form 4, filing 0001535610-18-000069 | |
| 2018-03-14 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 50,020 acquired | 0.42 | 21,013.40 | Form 4, filing 0001535610-18-000069 | |
| 2018-03-14 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 17,900 acquired | 0.42 | 7,589.60 | Form 4, filing 0001535610-18-000069 | |
| 2018-03-14 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 4,271 acquired | 0.42 | 1,793.82 | Form 4, filing 0001535610-18-000069 | |
| 2018-03-14 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 800 acquired | 0.42 | 335.92 | Form 4, filing 0001535610-18-000069 | |
| 2018-03-14 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 200 acquired | 0.42 | 84.00 | Form 4, filing 0001535610-18-000069 | |
| 2018-03-13 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 30,990 acquired | 0.42 | 13,025.10 | Form 4, filing 0001535610-18-000068 | |
| 2018-03-13 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 6,329 acquired | 0.42 | 2,658.18 | Form 4, filing 0001535610-18-000068 | |
| 2018-03-12 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 24,600 acquired | 0.42 | 10,295.10 | Form 4, filing 0001535610-18-000068 | |
| 2018-03-12 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 24,162 acquired | 0.42 | 10,114.21 | Form 4, filing 0001535610-18-000068 | |
| 2018-03-12 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 21,800 acquired | 0.41 | 8,975.06 | Form 4, filing 0001535610-18-000068 | |
| 2018-03-12 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 20,373 acquired | 0.42 | 8,554.62 | Form 4, filing 0001535610-18-000068 | |
| 2018-03-12 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 12,390 acquired | 0.41 | 5,081.14 | Form 4, filing 0001535610-18-000068 | |
| 2018-03-12 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 11,521 acquired | 0.41 | 4,723.61 | Form 4, filing 0001535610-18-000068 | |
| 2018-03-12 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 10,605 acquired | 0.42 | 4,442.43 | Form 4, filing 0001535610-18-000068 | |
| 2018-03-12 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 10,000 acquired | 0.42 | 4,200.00 | Form 4, filing 0001535610-18-000068 | |
| 2018-03-12 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 2,604 acquired | 0.42 | 1,093.42 | Form 4, filing 0001535610-18-000068 | |
| 2018-03-12 |
Rosetta Genomics Ltd. ROSG |
P, Open-market purchase | 454 acquired | 0.40 | 182.05 | Form 4, filing 0001535610-18-000068 | |
| 2014-04-15 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 17,100 acquired | 5.00 | 85,500.00 | Form 4, filing 0001535610-14-000056 | |
| 2014-04-14 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 3,000 acquired | 5.21 | 15,630.00 | Form 4, filing 0001535610-14-000056 | |
| 2014-04-11 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 100 acquired | 5.15 | 515.00 | Form 4, filing 0001535610-14-000055 | |
| 2014-04-10 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 1,400 acquired | 5.25 | 7,350.00 | Form 4, filing 0001535610-14-000055 | |
| 2014-04-09 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 1,075 acquired | 5.51 | 5,923.25 | Form 4, filing 0001535610-14-000055 | |
| 2014-04-08 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 35,500 acquired | 5.36 | 190,280.00 | Form 4, filing 0001535610-14-000054 | |
| 2014-04-07 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 16,900 acquired | 5.64 | 95,316.00 | Form 4, filing 0001535610-14-000054 | |
| 2014-04-07 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 3,754 acquired | 6.00 | 22,524.00 | Form 4, filing 0001535610-14-000054 | |
| 2014-04-04 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 11,250 acquired | 6.08 | 68,400.00 | Form 4, filing 0001535610-14-000054 | |
| 2014-04-04 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 1,000 acquired | 6.00 | 6,000.00 | Form 4, filing 0001535610-14-000054 | |
| 2014-04-02 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 2,500 acquired | 6.15 | 15,375.00 | Form 4, filing 0001535610-14-000052 | |
| 2014-04-01 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 7,496 acquired | 6.12 | 45,875.52 | Form 4, filing 0001535610-14-000052 | |
| 2014-04-01 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 7,375 acquired | 6.08 | 44,840.00 | Form 4, filing 0001535610-14-000052 | |
| 2014-04-01 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 500 acquired | 6.18 | 3,090.00 | Form 4, filing 0001535610-14-000052 | |
| 2014-03-31 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 7,936 acquired | 6.35 | 50,393.60 | Form 4, filing 0001535610-14-000052 | |
| 2014-03-27 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 1,700 acquired | 6.61 | 11,237.00 | Form 4, filing 0001535610-14-000051 | |
| 2014-03-26 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 13,300 acquired | 6.65 | 88,445.00 | Form 4, filing 0001535610-14-000051 | |
| 2014-03-26 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 900 acquired | 6.86 | 6,174.00 | Form 4, filing 0001535610-14-000051 | |
| 2014-03-25 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 303 acquired | 6.90 | 2,090.70 | Form 4, filing 0001535610-14-000051 | |
| 2014-03-24 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 2,400 acquired | 6.71 | 16,104.00 | Form 4, filing 0001535610-14-000050 | |
| 2014-03-21 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 4,900 acquired | 6.83 | 33,467.00 | Form 4, filing 0001535610-14-000050 | |
| 2014-03-20 |
Celsus Therapeutics Plc. CLTX |
P, Open-market purchase | 3,800 acquired | 6.90 | 26,220.00 | Form 4, filing 0001535610-14-000050 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Sabby Healthcare Master Fund, Ltd., insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001561018
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6